178 related articles for article (PubMed ID: 25252953)
1. Structural and functional analyses of biosimilar enoxaparins available in Brazil.
Oliveira SN; Santos GR; Glauser BF; Capillé NV; Queiroz IN; Pereira MS; Pomin VH; Mourão PA
Thromb Haemost; 2015 Jan; 113(1):53-65. PubMed ID: 25252953
[TBL] [Abstract][Full Text] [Related]
2. Update on Brazilian biosimilar enoxaparins.
Vilanova E; Glauser BF; Oliveira SM; Tovar AM; Mourão PA
Expert Rev Hematol; 2016 Nov; 9(11):1015-1021. PubMed ID: 27680213
[TBL] [Abstract][Full Text] [Related]
3. Structure and haemostatic effects of generic versions of enoxaparin available for clinical use in Brazil: similarity to the original drug.
Glauser BF; Vairo BC; Oliveira SN; Cinelli LP; Pereira MS; Mourão PA
Thromb Haemost; 2012 Feb; 107(2):302-14. PubMed ID: 22234635
[TBL] [Abstract][Full Text] [Related]
4. Heparin from bovine intestinal mucosa: glycans with multiple sulfation patterns and anticoagulant effects.
Tovar AM; Capillé NV; Santos GR; Vairo BC; Oliveira SN; Fonseca RJ; Mourão PA
Thromb Haemost; 2012 May; 107(5):903-15. PubMed ID: 22437650
[TBL] [Abstract][Full Text] [Related]
5. Propositional debate on biosimilar enoxaparin in Brazil.
Mourão PA; Glauser BF; Vairo BC; Pereira MS
Arq Bras Cardiol; 2012 Jan; 98(1):e11-4. PubMed ID: 22323327
[TBL] [Abstract][Full Text] [Related]
6. Comparative subcutaneous repeated toxicity study of enoxaparin products in rats.
Kobbi Z; Kraiem H; Benlasfar Z; Marouani A; Massoud T; Boubaker S; Bouhaouala-Zahar B; Fenina N
Regul Toxicol Pharmacol; 2017 Mar; 84():9-17. PubMed ID: 27965129
[TBL] [Abstract][Full Text] [Related]
7. Slight differences in sulfation of algal galactans account for differences in their anticoagulant and venous antithrombotic activities.
Fonseca RJ; Oliveira SN; Melo FR; Pereira MG; Benevides NM; Mourão PA
Thromb Haemost; 2008 Mar; 99(3):539-45. PubMed ID: 18327402
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves.
McKellar SH; Abel S; Camp CL; Suri RM; Ereth MH; Schaff HV
J Thorac Cardiovasc Surg; 2011 Jun; 141(6):1410-6. PubMed ID: 21429525
[TBL] [Abstract][Full Text] [Related]
9. Influence of molecular weight of chemically sulfated citrus pectin fractions on their antithrombotic and bleeding effects.
Cipriani TR; Gracher AH; de Souza LM; Fonseca RJ; Belmiro CL; Gorin PA; Sassaki GL; Iacomini M
Thromb Haemost; 2009 May; 101(5):860-6. PubMed ID: 19404539
[TBL] [Abstract][Full Text] [Related]
10. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
Melo FR; Mourão PA
Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
[TBL] [Abstract][Full Text] [Related]
11. Effects of polysaccharides enriched in 2,4-disulfated fucose units on coagulation, thrombosis and bleeding. Practical and conceptual implications.
Fonseca RJ; Santos GR; Mourão PA
Thromb Haemost; 2009 Nov; 102(5):829-36. PubMed ID: 19888516
[TBL] [Abstract][Full Text] [Related]
12. Construction and functional evaluation of hirudin derivatives with low bleeding risk.
Zhang C; Yu A; Yuan B; Dong C; Yu H; Wang L; Wu C
Thromb Haemost; 2008 Feb; 99(2):324-30. PubMed ID: 18278181
[TBL] [Abstract][Full Text] [Related]
13. Fucosylated chondroitin sulfate as a new oral antithrombotic agent.
Fonseca RJ; Mourão PA
Thromb Haemost; 2006 Dec; 96(6):822-9. PubMed ID: 17139379
[TBL] [Abstract][Full Text] [Related]
14. Thromboelastographic evaluation of blood coagulation in the presence of branded and generic enoxaparins.
Walenga JM; Jeske WP; Escalante V; Hoppensteadt D; Fareed J; Bakhos M
Int Angiol; 2012 Dec; 31(6):517-25. PubMed ID: 23222929
[TBL] [Abstract][Full Text] [Related]
15. Low-molecular-weight heparin biosimilars: potential implications for clinical practice. Australian Low-Molecular-Weight Heparin Biosimilar Working Group (ALBW).
Nandurkar H; Chong B; Salem H; Gallus A; Ferro V; McKinnon R;
Intern Med J; 2014 May; 44(5):497-500. PubMed ID: 24816308
[TBL] [Abstract][Full Text] [Related]
16. Antithrombin and heparin cofactor II-mediated inactivation of alpha-thrombin by a synthetic, sulfated mannogalactan.
Gracher AH; Cipriani TR; Carbonero ER; Gorin PA; Iacomini M
Thromb Res; 2010 Sep; 126(3):e180-7. PubMed ID: 20553946
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic P-selectin inhibition with PSI-421 promotes resolution of venous thrombosis without anticoagulation.
Meier TR; Myers DD; Wrobleski SK; Zajkowski PJ; Hawley AE; Bedard PW; Ballard NE; Londy FJ; Kaila N; Vlasuk GP; Schaub RG; Wakefield TW
Thromb Haemost; 2008 Feb; 99(2):343-51. PubMed ID: 18278184
[TBL] [Abstract][Full Text] [Related]
18. [Low-molecular-weight heparin - enoxaparin (clexane) in the prevention of thromboembolic complications in surgical patients].
Zabolotskikh IB; Sin'kov SV; Klevko VA
Anesteziol Reanimatol; 2001; (2):70-5. PubMed ID: 11494909
[No Abstract] [Full Text] [Related]
19. Pharmacological actions of sulodexide.
Ofosu FA
Semin Thromb Hemost; 1998; 24(2):127-38. PubMed ID: 9579633
[TBL] [Abstract][Full Text] [Related]
20. [Is there a difference between low-molecular-weight heparins?].
Eritsland J
Tidsskr Nor Laegeforen; 2005 Oct; 125(20):2802-3. PubMed ID: 16244685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
